secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001104659-23-059454
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics Q1 net loss $7.5M; advances AJ201 and IV Tramadol programs
------------------------------------------------------------------------------

- Net loss of $7.5M ($1.37 per share) vs $2.9M loss ($2.05 per share) in Q1 2022.
- Cash and equivalents $8.2M at March 31, 2023, up from $6.7M at December 31, 2022.
- R&D expenses $1.2M plus $4.2M in licenses acquired (AJ201) vs $1.8M prior-year period.
- Entered exclusive license for AJ201 (SBMA treatment); Phase 1b/2a trial ongoing; FDA orphan drug designation.
- FDA agreed on most aspects of IV Tramadol safety confirmatory trial protocol; pending final statistical analysis plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465923059454/0001104659-23-059454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465923059454/tm2315281d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-059454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer